A Phase 4 interventional study of Remimazolam besylate and Propofol in Burn Scar, Hypertrophic Scarring and Procedural Sedation, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Medical University of South Carolina · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Cicatrix, Hypertrophic with a site in United States — 7 open to participants now, 8 under way, 2 of them phase 3. Cicatrix, Hypertrophic · United States.
Among the 38 studies in Cicatrix, Hypertrophic with a site in United States, this one has the largest planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 4, and was the 37th registered.
129 studies on the registry are indexed under Cicatrix, Hypertrophic; 31 are open to participants now.
Browse Cicatrix, Hypertrophic studies →7 of the 38 studies in Cicatrix, Hypertrophic with a site in United States are open now. Recruiting first, the newest first:
Sonal Choudhary · Sites in United States
Ages 18+
Iran University of Medical Sciences · Sites in United States, Iran, Islamic Republic of
Ages 20–60
Medstar Health Research Institute · Sites in United States
Ages 18+
Melissa Pugliano-Mauro · Sites in United States
Ages 18+ · Healthy volunteers
Tirgan, Michael H., M.D. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Cicatrix, Hypertrophic studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 3 · Phase 4 3
First in 2006; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 136 is above the median of 36 across 106 interventional studies indexed under Cicatrix, Hypertrophic.
Median enrollment 22 across the 35 interventional studies, 1,000 across the 3 observational. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 38 have an industry lead sponsor. The 10 most frequent:
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
Medical University of South Carolina has 1 study filed under Cicatrix, Hypertrophic — fewer than ten, so there is no comparison to draw.
3 of the studies in Cicatrix, Hypertrophic with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05478551Phase 3Henry Ford Health SystemRandomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization | 2026-12-30 |
| NCT07336368Phase 3Sonal ChoudharyTopical Cryotherapy and Keloid/Hypertrophic Scars | 2027-06 |
| NCT03561376Melissa Pugliano-MauroZinc Oxide Versus Petrolatum Following Skin Surgery | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Cicatrix, Hypertrophic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust/chin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \< 8).
Patients will be randomized to receive either remimazolam or propofol during their first laser session, and the alternate drug during their second session 4-6 weeks later. Outcomes include respiratory depression, sedation onset and recovery times, hemodynamic changes, and patient satisfaction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be randomized to receive Remimazolam 0.075 mg/kg (maximum of 5 mg) for sedation during their first laser therapy session, then 4-6 weeks later at their next laser therapy session they will receive propofol 0.8 mg/kg IV bolus for sedation.
Drug: Remimazolam besylate · Drug: Propofol
Patients will be randomized to receive Propofol 0.8 mg/kg IV bolus for sedation during their first laser therapy session, then 4-6 weeks later at their next laser therapy session they will receive Remimazolam 0.075 mg/kg (maximum of 5 mg) for sedation.
Drug: Remimazolam besylate · Drug: Propofol
Remimazolam
Propofol
Incidence of respiratory depression
The incidence of respiratory depression will include need for advanced airway maneuvers, or hypopnea events. Advanced airway maneuvers during the laser therapy procedure may include jaw thrust, chin lift, insertion of oral or nasal airway, or bag mask ventilation. A hypopnea event is defined as a respiratory rate \<8.
Time frame: up to 24 hours after procedure ends
Time from initiation of sedation to peak sedation
Time from initiation of sedation to peak sedation will be measured in minutes and calculated from the start time of induction to peak sedation when patient reaches a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score of less than 3. The MOAA/S scale ranges from 0 to 5, with higher scores indicating greater alertness and lower scores indicating deeper sedation: 5: Responds readily to name spoken in a normal tone. 4: Lethargic response to name spoken in a normal tone. 3: Responds only after name is called loudly or repeatedly. 2: Responds only after mild prodding or shaking. 1: Responds only after a painful trapezius squeeze. 0: Does not respond to a painful trapezius squeeze.
Time frame: up to 24 hours after procedure ends
Time of cessation of sedation to full recovery
Time of cessation of sedation to full recovery will be evaluated in minutes by marking when the last dose of anesthetic medication is given (cessation of sedation), to when the patient has reached full recovery from anesthesia. Full recovery from anesthesia is defined as when the patient reaches a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≥ 4. The MOAA/S scale ranges from 0 to 5, with higher scores indicating greater alertness and lower scores indicating deeper sedation: 5: Responds readily to name spoken in a normal tone. 4: Lethargic response to name spoken in a normal tone. 3: Responds only after name is called loudly or repeatedly. 2: Responds only after mild prodding or shaking. 1: Responds only after a painful trapezius squeeze. 0: Does not respond to a painful trapezius squeeze.
Time frame: up to 24 hours after procedure ends
Cessation of sedation to full recovery
Cessation of sedation to full recovery will also be evaluated as length of PACU stay. This will be measured from the time the patient left the procedure room, to the time they are ready for discharge (marked as procedural care complete).
Time frame: up to 24 hours after the procedure ends
Satisfaction with Anesthesia
Satisfaction with Anesthesia will be measured using the Iowa Satisfaction with Anesthesia Scale (ISAS) approximately 15 minutes to two hours after arrival to to the recovery unit. This measures their satisfaction with Monitored Anesthesia Care (MAC). ISAS is an 11-item questionnaire designed to measure the satisfaction with monitored anesthesia care. The ISAS score is the mean of responses to all 11 questions. The score ranges from a minimum of -3 to a maximum of +3 when averaged together. The responses are: -3 = disagree very much, -2 = disagree moderately, -1 = disagree slightly, 1 = agree slightly, 2 = agree moderately, and 3 = agree very much. A score of +3 would imply a completely satisfied patient.
Time frame: up to 24 hours after the procedure ends
Felling pain on injection of sedation medication
Subjects will be asked if they felt pain upon the injection of the sedation medications, and will answer "yes" or "no". This will be asked at least 15 minutes after arriving to the recovery area after the procedure. "No" indicates they did not feel pain upon injection which means a better outcome.
Time frame: up to 24 hours after the procedure ends
Incidence of hypotension
Incidence of hypotension during the procedure will measured by the use of vasopressors such as Norepinephrine or equivalent, as well as the lowest blood pressure reading during the procedure.
Time frame: up to 24 hours after the procedure ends
Incidence of low EtCO2
Incidence of low EtCO2 will be measured by recording the lowest intraoperative EtCO2 reading during the procedure.
Time frame: up to 24 hours after the procedure ends
Incidence of hypoxemia
Baseline SpO2 and lowest SpO2 will be recorded to evaluate incidence of hypoxemia during the procedure.
Time frame: up to 24 hours after the procedure ends
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jan 2028, 25 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jan 2027 → Jan 2028 and completion Jan 2027 → Jan 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Remimazolam besilate · Propofol
Medical University of South Carolina →